GENESIS CAPITAL has entered the pharmaceutical segment. Its fund Genesis Private Equity Fund III (GPEF III) has purchased a 75% stake in Czech company QUINTA-ANALYTICA, which specializes in analytical services and clinical studies during the development and production of new drugs. This is the first investment of the new fund which will offer small and medium-sized companies roughly EUR 80m. The largest customers for the services of QUINTA-ANALYTICA are producers of drugs and contractual research organizations primarily from Europe.
